New results from a Phase 1 clinical trial that tested Eli Lilly’s investigational CDK4/6...
The recent legalization of cannabis for medical purposes in some US states has reinvigorated the...
Joseph Papa shed on light on the potential strategy for reducing the drug maker's debt load.
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars.
Europe's main drug regulator has lifted a 7-year-old warning about possible suicidal risks from Chantix, Pfizer's smoking-cessation pill.
For the first time scientists have identified a molecule that promotes the progression of the disease which affects 6,500 people in the UK.
Combination approaches have the potential to generate twice as many sales in the recurrent RCC market.
Janssen Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving Stelara (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
The spread of yellow fever is a global health threat.
“Cure” is a word that’s dominated the rhetoric in the war on cancer for decades.
All three firms aim to contribute to the enhancement of health and welfare of people around the world through creating innovative medicine.
The technology addresses the profound challenge of drug resistance among HIV-infected patients in resource-poor areas.
The group is now working with US clinical stage biotechnology company PharmaCyte Biotech to commercialize the research.
This decision was made less than a year after regulatory approvals.
This drug is projected to be an important source of revenue for Novo Nordisk.